BillionToOne, Inc. (BLLN) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $74.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: molecular diagnostic tests; Earnings in 6 days (event risk).
BillionToOne provides molecular diagnostics via its smNGS platform, with prenatal (UNITY) and oncology (Northstar) product lines. Revenue derives primarily from third-party payor reimbursements for diagnostic tests, representing more than 90% of revenue. The company transitioned... Read more
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $74.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: molecular diagnostic tests; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductmolecular diagnostic tests10-K Item 1A: 'We primarily generate revenue from sales of our molecular diagnostic tests and we are highly dependent on them for our success.'
Material Events(8-K, last 90d)
- 2026-03-04Item 5.02LOWOn March 4, 2026, BillionToOne's Board adopted the BillionToOne Annual Incentive Plan effective for performance periods beginning January 1, 2026, for executive officers and other designated employees. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $74.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: molecular diagnostic tests; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $69.55. Score 5.6/10, moderate confidence.
Take-profit target: $101.54 (+35.8% upside). Prior stop was $69.55. Stop-loss: $69.55.
Concentration risk — Product: molecular diagnostic tests; Earnings in 6 days (event risk); Negative momentum.
BillionToOne, Inc. trades at a P/E of 526.5 (forward 82.4). TrendMatrix value score: 5.1/10. Verdict: Sell.
14 analysts cover BLLN with a consensus score of 4.2/5. Average price target: $117.
What does BillionToOne, Inc. do?BillionToOne provides molecular diagnostics via its smNGS platform, with prenatal (UNITY) and oncology (Northstar)...
BillionToOne provides molecular diagnostics via its smNGS platform, with prenatal (UNITY) and oncology (Northstar) product lines. Revenue derives primarily from third-party payor reimbursements for diagnostic tests, representing more than 90% of revenue. The company transitioned from R&D to commercial stage since launching UNITY in 2019.